These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25451655)

  • 1. Reply: To PMID 24818764.
    Sanyal AJ;
    Gastroenterology; 2015 Jan; 148(1):262-3. PubMed ID: 25451655
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials.
    Rowe IA; Parker R
    Gastroenterology; 2015 Jan; 148(1):262. PubMed ID: 25451662
    [No Abstract]   [Full Text] [Related]  

  • 3. Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice.
    Kajikawa S; Harada T; Kawashima A; Imada K; Mizuguchi K
    Prostaglandins Leukot Essent Fatty Acids; 2009 Apr; 80(4):229-38. PubMed ID: 19328666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice.
    Soni NK; Nookaew I; Sandberg AS; Gabrielsson BG
    Lipids Health Dis; 2015 Jul; 14():74. PubMed ID: 26193881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice.
    Rodriguez-Echevarria R; Macias-Barragan J; Parra-Vargas M; Davila-Rodriguez JR; Amezcua-Galvez E; Armendariz-Borunda J
    World J Gastroenterol; 2018 Jan; 24(4):461-474. PubMed ID: 29398867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.
    Tanaka N; Sano K; Horiuchi A; Tanaka E; Kiyosawa K; Aoyama T
    J Clin Gastroenterol; 2008 Apr; 42(4):413-8. PubMed ID: 18277895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Omega-3 fatty acids as an option in the treatment of NAFLD].
    Singer P
    MMW Fortschr Med; 2011 Oct; 153 Suppl 3():90-4. PubMed ID: 22184802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Authors' reply.
    Ballantyne CM; Bays HE; Braeckman RA; Soni PN
    Am J Cardiol; 2013 Feb; 111(3):455-6. PubMed ID: 23317532
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver.
    Kurihara T; Adachi Y; Yamagata M; Abe K; Akimoto M; Hashimoto H; Ishiguro H; Niimi A; Maeda A; Shigemoto M
    Clin Ther; 1994; 16(5):830-7. PubMed ID: 7859243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptin: is it a possible specific liver drug for non-alcoholic fatty liver disease (NAFLD)?
    Xin YN; Xuan SY; Guan HS
    Med Hypotheses; 2008 Sep; 71(3):462-3. PubMed ID: 18511214
    [No Abstract]   [Full Text] [Related]  

  • 11. Decrease of eicosapentaenoic acid in fatty liver of diabetic subjects.
    Singer P; Honigmann G; Schliack V
    Prostaglandins Med; 1980 Sep; 5(3):183-200. PubMed ID: 6251498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and hepatotoxicity: focus on patients with fatty liver.
    Chalasani N
    Hepatology; 2005 Apr; 41(4):690-5. PubMed ID: 15789367
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of 4 weeks' intake of polyunsaturated fatty acid ethylester rich in eicosapentaenoic acid (ethylester) on plasma lipids, plasma and platelet phospholipid fatty acid composition and platelet aggregation; a double blind study].
    Kawamura M; Naito C; Hayashi H; Hashimoto Y; Kato H; Matsushima T
    Nihon Naika Gakkai Zasshi; 1983 Jan; 72(1):18-24. PubMed ID: 6343532
    [No Abstract]   [Full Text] [Related]  

  • 14. [Eicosapentaenoic acid].
    Tsushima M
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():650-6. PubMed ID: 11347148
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.
    Sofi F; Giangrandi I; Cesari F; Corsani I; Abbate R; Gensini GF; Casini A
    Int J Food Sci Nutr; 2010 Dec; 61(8):792-802. PubMed ID: 20465434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of cholineorotate on experimental fatty liver in the rat].
    Petzold H; Storch H; Hohlfeld R
    Z Gesamte Inn Med; 1970 Aug; 25(15):697-700. PubMed ID: 4269665
    [No Abstract]   [Full Text] [Related]  

  • 17. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
    Abenavoli L; Bellentani S
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):677-9. PubMed ID: 24134155
    [No Abstract]   [Full Text] [Related]  

  • 18. Cide-a and Cide-c are induced in the progression of hepatic steatosis and inhibited by eicosapentaenoic acid.
    Jinno Y; Nakakuki M; Sato A; Kawano H; Notsu T; Mizuguchi K; Shimano H
    Prostaglandins Leukot Essent Fatty Acids; 2010 Aug; 83(2):75-81. PubMed ID: 20542418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply: To PMID 25865049.
    Vilar-Gomez E; Friedman SL; Romero-Gomez M
    Gastroenterology; 2015 Dec; 149(7):1988-9. PubMed ID: 26515488
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucagon like-peptide 1 receptor and the liver.
    Pedersen J; Holst JJ
    Liver Int; 2011 Oct; 31(9):1243-5. PubMed ID: 22093450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.